tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 109 participants.

Also called NCT04248868

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 109 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04248868
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04248868. Allocation not applicable; no masking; primary purpose treatment. Start 2020-06-23 (actual); primary completion 2022-06-22 (actual). Results posted on 2023-04-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
Acronym
RESCUE
Intervention (Device)
The Bashir™ Endovascular Catheter
Intervention (Drug)
r-tPA
Lead sponsor
Thrombolex, Inc. (class: industry)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct04248868
Content hash
ebc6cd0982fa2c7b9818c13b9458a0c6ce0a7212d5655519034d5e1bb3527dd5